CLAIMS

1. A peptide comprising the amino acid sequence of SEQ ID NO: 12.

2. The peptide of claim 1, wherein the peptide is capable of activating a GLP-1 receptor and a glucagon receptor.

3. The peptide of claim 1 or 2, for use in the treatment of obesity.

4. The peptide of claim 1 or 2, wherein at least one amino acid pair at positions 12 and 16 or 16 and 20 of the peptide forms a ring.

5. A pharmaceutical composition comprising the peptide of any one of claims 1, 2 or 4 as an active ingredient.

6. The pharmaceutical composition of claim 5, further comprising a pharmaceutically acceptable carrier.

7. Use of the peptide of any one of claims 1, 2 or 4 or the pharmaceutical composition of claim 5 or 6 in the manufacture of a medicament for the treatment of obesity wherein the medicament is to be administered alone or in combination with pharmaceutical formulations exhibiting an effect of treating obesity.

8. The use of claim 7, wherein the pharmaceutical formulation is a GLP-1 receptor agonist, a leptin receptor agonist, a DPP-IV inhibitor, a Y5 receptor antagonist, a melanin-concentrating hormone (MCH) receptor antagonist, a Y2/3 receptor agonist, an MC3/4 receptor agonist, a gastric/pancreatic lipase inhibitor, a 5HT2c agonist, a 3A receptor agonist, an amylin receptor agonist, a ghrelin antagonist, or a ghrelin receptor antagonist.